Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2005 Mar;60(3):193–198. doi: 10.1136/thx.2004.032516

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

C Brightling 1, S McKenna 1, B Hargadon 1, S Birring 1, R Green 1, R Siva 1, M Berry 1, D Parker 1, W Monteiro 1, I Pavord 1, P Bradding 1
PMCID: PMC1747331  PMID: 15741434

Abstract

Background: An association between the sputum eosinophil count and the response to a 2 week course of prednisolone has previously been reported in patients with chronic obstructive pulmonary disease (COPD). Whether the response to inhaled corticosteroids is related to the presence of eosinophilic inflammation is unclear.

Methods: A randomised, double blind, crossover trial of placebo and mometasone furoate (800 µg/day), each given for 6 weeks with a 4 week washout period, was performed in subjects with COPD treated with bronchodilator therapy only. Spirometric tests, symptom scores, chronic respiratory disease questionnaire (CRQ), and induced sputum were performed before and after each treatment phase.

Results: Ninety five patients were recruited of which 60 were randomised. Overall there were no treatment associated changes in forced expiratory volume in 1 second (FEV1), total CRQ, or sputum characteristics. After stratification into tertiles by baseline eosinophil count, the net improvement in post-bronchodilator FEV1 increased with mometasone compared with placebo progressively from the least to the most eosinophilic tertile. The mean change in post-bronchodilator FEV1 with mometasone compared with placebo in the highest tertile was 0.11 l (95% CI 0.03 to 0.19). This improvement was not associated with a fall in the sputum eosinophil count.

Conclusions: An increased sputum eosinophil count is related to an improvement in post-bronchodilator FEV1 following treatment with inhaled mometasone in COPD, but the improvement is not associated with a reduction in the sputum eosinophil count.

Full Text

The Full Text of this article is available as a PDF (110.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brightling C. E., Monteiro W., Ward R., Parker D., Morgan M. D., Wardlaw A. J., Pavord I. D. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000 Oct 28;356(9240):1480–1485. doi: 10.1016/S0140-6736(00)02872-5. [DOI] [PubMed] [Google Scholar]
  2. Brightling C. E., Ward R., Goh K. L., Wardlaw A. J., Pavord I. D. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med. 1999 Aug;160(2):406–410. doi: 10.1164/ajrccm.160.2.9810100. [DOI] [PubMed] [Google Scholar]
  3. Brightling C. E., Ward R., Woltmann G., Bradding P., Sheller J. R., Dworski R., Pavord I. D. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):878–882. doi: 10.1164/ajrccm.162.3.9909064. [DOI] [PubMed] [Google Scholar]
  4. Burge P. S., Calverley P. M. A., Jones P. W., Spencer S., Anderson J. A. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003 Aug;58(8):654–658. doi: 10.1136/thorax.58.8.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burge P. S., Calverley P. M., Jones P. W., Spencer S., Anderson J. A., Maslen T. K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297–1303. doi: 10.1136/bmj.320.7245.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Calverley P. M. A., Walker Paul. Chronic obstructive pulmonary disease. Lancet. 2003 Sep 27;362(9389):1053–1061. doi: 10.1016/s0140-6736(03)14416-9. [DOI] [PubMed] [Google Scholar]
  7. Confalonieri M., Mainardi E., Della Porta R., Bernorio S., Gandola L., Beghè B., Spanevello A. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax. 1998 Jul;53(7):583–585. doi: 10.1136/thx.53.7.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Culpitt S. V., Maziak W., Loukidis S., Nightingale J. A., Matthews J. L., Barnes P. J. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1635–1639. doi: 10.1164/ajrccm.160.5.9811058. [DOI] [PubMed] [Google Scholar]
  9. Fan Vincent S., Bryson Chris L., Curtis J. Randall, Fihn Stephan D., Bridevaux Pierre-Olivier, McDonell Mary B., Au David H. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med. 2003 Oct 2;168(12):1488–1494. doi: 10.1164/rccm.200301-019OC. [DOI] [PubMed] [Google Scholar]
  10. Gizycki M. J., Hattotuwa K. L., Barnes N., Jeffery P. K. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax. 2002 Sep;57(9):799–803. doi: 10.1136/thorax.57.9.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Green Ruth H., Brightling Christopher E., McKenna Susan, Hargadon Beverley, Parker Debbie, Bradding Peter, Wardlaw Andrew J., Pavord Ian D. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002 Nov 30;360(9347):1715–1721. doi: 10.1016/S0140-6736(02)11679-5. [DOI] [PubMed] [Google Scholar]
  12. Guyatt G. H., Berman L. B., Townsend M., Pugsley S. O., Chambers L. W. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987 Oct;42(10):773–778. doi: 10.1136/thx.42.10.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jones P. W., Willits L. R., Burge P. S., Calverley P. M. A., Inhaled Steroids in Obstructive Lung Disease in Europe study investigators Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003 Jan;21(1):68–73. doi: 10.1183/09031936.03.00013303. [DOI] [PubMed] [Google Scholar]
  14. Keatings V. M., Barnes P. J. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med. 1997 Feb;155(2):449–453. doi: 10.1164/ajrccm.155.2.9032177. [DOI] [PubMed] [Google Scholar]
  15. Keatings V. M., Jatakanon A., Worsdell Y. M., Barnes P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997 Feb;155(2):542–548. doi: 10.1164/ajrccm.155.2.9032192. [DOI] [PubMed] [Google Scholar]
  16. Loppow D., Schleiss M. B., Kanniess F., Taube C., Jörres R. A., Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med. 2001 Feb;95(2):115–121. doi: 10.1053/rmed.2000.0960. [DOI] [PubMed] [Google Scholar]
  17. Louis R. E., Cataldo D., Buckley M. G., Sele J., Henket M., Lau L. C., Bartsch P., Walls A. F., Djukanovic R. Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease. Eur Respir J. 2002 Aug;20(2):325–331. doi: 10.1183/09031936.02.00286302. [DOI] [PubMed] [Google Scholar]
  18. Mahler Donald A., Wire Patrick, Horstman Donald, Chang Chai-Ni, Yates Julie, Fischer Tracy, Shah Tushar. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 Oct 15;166(8):1084–1091. doi: 10.1164/rccm.2112055. [DOI] [PubMed] [Google Scholar]
  19. Pauwels R. A., Buist A. S., Calverley P. M., Jenkins C. R., Hurd S. S., GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276. doi: 10.1164/ajrccm.163.5.2101039. [DOI] [PubMed] [Google Scholar]
  20. Pauwels R. A., Löfdahl C. G., Laitinen L. A., Schouten J. P., Postma D. S., Pride N. B., Ohlsson S. V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948–1953. doi: 10.1056/NEJM199906243402503. [DOI] [PubMed] [Google Scholar]
  21. Pavord I. D., Brightling C. E., Woltmann G., Wardlaw A. J. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999 Jun 26;353(9171):2213–2214. doi: 10.1016/S0140-6736(99)01813-9. [DOI] [PubMed] [Google Scholar]
  22. Pavord I. D., Siva R., Brightling C. E. Prednisolone response in patients with COPD. Thorax. 2004 Feb;59(2):179–179. doi: 10.1136/thx.2003.019414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pizzichini E., Pizzichini M. M., Gibson P., Parameswaran K., Gleich G. J., Berman L., Dolovich J., Hargreave F. E. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1511–1517. doi: 10.1164/ajrccm.158.5.9804028. [DOI] [PubMed] [Google Scholar]
  24. Soriano J. B., Vestbo J., Pride N. B., Kiri V., Maden C., Maier W. C. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002 Oct;20(4):819–825. doi: 10.1183/09031936.02.00301302. [DOI] [PubMed] [Google Scholar]
  25. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., Peterson S., Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003 Jan;21(1):74–81. doi: 10.1183/09031936.03.00031402. [DOI] [PubMed] [Google Scholar]
  26. Tweeddale P. M., Alexander F., McHardy G. J. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax. 1987 Jul;42(7):487–490. doi: 10.1136/thx.42.7.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Vestbo J., Sørensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999 May 29;353(9167):1819–1823. doi: 10.1016/s0140-6736(98)10019-3. [DOI] [PubMed] [Google Scholar]
  28. Yildiz F., Kaur A. C., Ilgazli A., Celikoglu M., Kaçar Ozkara S., Paksoy N., Ozkarakaş O. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration. 2000;67(1):71–76. doi: 10.1159/000029466. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES